A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Blood
; 123(22): 3398-405, 2014 May 29.
Article
in En
| MEDLINE
| ID: mdl-24615778
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Purines
/
Lymphoma, Mantle-Cell
/
Quinazolinones
/
Phosphoinositide-3 Kinase Inhibitors
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Blood
Year:
2014
Type:
Article